Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 4 · 57.1%High 0 · 0%

CMV disease · solid organ transplant recipients

Extended probably leads to lower CMV disease compared with short‐duration valganciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.2 [0.12, 0.35]
2 studies · 454 participants
Moderate

All‐cause death · solid organ transplant recipients

Extended showed no clear difference in all‐cause death compared with short‐duration valganciclovir (low certainty).

1 finding from 1 review

CMV syndrome · solid organ transplant recipients

Extended probably leads to lower CMV syndrome compared with short‐duration valganciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.39 [0.24, 0.64]
2 studies · 454 participants
Moderate

CMV infection · solid organ transplant recipients

Extended may leads to lower CMV infection compared with short‐duration valganciclovir (low certainty).

1 finding from 1 review

Acute rejection · solid organ transplant recipients

Extended probably leads to lower acute rejection compared with short‐duration valganciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.64 [0.43, 0.95]
2 studies · 454 participants
Moderate

Opportunistic infections · solid organ transplant recipients

Extended showed no clear difference in opportunistic infections compared with short‐duration valganciclovir (low certainty).

1 finding from 1 review

Total treatment‐related adverse effects · solid organ transplant recipients

Extended showed no clear difference in total treatment‐related adverse effects compared with short‐duration valganciclovir (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 1.16 [0.97, 1.4]
2 studies · 456 participants
Moderate